Skip to content

Investor Relations / Publications / Other Publications Referenced in Amarin’s Investor Communications

Other Publications Referenced in Amarin’s Investor Communications

To search publications using the available search words, please click here:

Nathan D. Wong, Peter P. Toth MD, PhD , Ezra A. Amsterdam MD , on behalf of the American Society for Preventive Cardiology, Most Important Advances in Preventive Cardiology During this Past Decade: Viewpoint from the American Society for Preventive Cardiology, Trends in Cardiovascular Medicine (2019),doi: https://doi.org/10.1016/j.tcm.2019.11.013

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patientsCardiorenal Med. 2019; epub ahead of print.
https://www.karger.com/Article/FullText/502511

https://www.ncbi.nlm.nih.gov/pubmed/31450229

Budoff M, Brent Muhlestein J, Le VT, May HT, Roy S, Nelson JR. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clin Cardiol. 2018;1–7.
Free:

https://doi.org/10.1002/clc.22856

Amarin Corporation